Title:A Systematic Review of the Impact of Resveratrol on Viral
Hepatitis and Chronic Viral Hepatitis-related Hepatocellular
Carcinoma
Volume: 24
Author(s): Mohammad Darvishi, Majid Nouri, Rasoul Rahimi, Saeid Heidari-Soureshjani and Seyed Mahmood Reza Hashemi Rafsanjani*
Affiliation:
- Faculty of Medicine, Tehran Medical
Sciences, Islamic Azad University, Tehran, Iran
Keywords:
Resveratrol, hepatitis, viral replication, hepatocellular carcinoma, side effect
Abstract: Background: Resveratrol (RSV) is used for the treatment of various
diseases due to their anti-inflammatory and antioxidant activities. However, its
beneficial aspects on viral hepatitis have been less investigated.
Objective: This report reviews the impact of resveratrol on viral hepatitis and chronic
viral hepatitis-related hepatocellular carcinoma (HCC).
Methods: The systematic review was performed and reported according to the
PRISMA 2020 statement. Several core databases, such as Cochrane Library,
PubMed, Web of Science, EMBASE, and Scopus, were used for search on September
6, 2023. After extraction of the data, the desired information of the full text of the
studies was recorded in Excel, and the outcomes and mechanisms were reviewed.
Results: RSV inhibits viral replication through anti-HCV NS3 helicase activity,
maintains redox homeostasis via glutathione (GSH) synthesis, improves T and B cell
activity, and suppresses miR-155 expression. It also enhances viral replication by
enhancing hepatitis C virus (HCV) RNA transcription, activating sirtuin-1 (SIRT1),
which can increase peroxisome proliferator-activated receptor (PPAR), and SIRT1
activates the HBV X protein (HBx). Moreover, RSV is responsible for hepatitis-related
HCC proliferation via suppression of mammalian target of rapamycin (mTOR), SIRT1
up-regulation, inhibiting expression of HBx, and reducing expression of cyclin D1.
Conclusion: Despite the promising properties of RSV in inhibiting hepatitis-related
HCC cell proliferation, its antiviral effects in viral hepatitis are controversial. The antihepatitis
behaviors of RSV are mainly dose-dependent, and in some studies, activating
some hepatoprotective pathways increases the transcription and replication of chronic
HBV and HCV. Therefore, healthcare providers should be aware of viral hepatitis
before using RSV supplements.
